Scientists in the U.K. say that AstraZeneca's drug olaparib, approved by the FDA late last year to treat ovarian cancer and sold as Lynparza, has demonstrated distinct signs of efficacy in a small and very targeted group of prostate cancer patients who share a distinct type of genetic mutation.
As it works to bring its prostate cancer vaccine Prostvac to market and expand its smallpox vaccine business, Danish vaccine maker Bavarian Nordic encountered a new set of challenges this week. Despite a billion-dollar partnership with Bristol-Myers Squibb, it's is the target of a short-selling campaign.
After ringing up a key U.S. approval in September to threaten Johnson & Johnson's Zytiga, Astellas' Xtandi now has what it needs to ramp up its market-share battle in the EU, too.
Nymox Pharmaceutical is headed for a bruising opening this morning after putting out word on Sunday that both their late-stage studies of their lead drug flopped as a treatment for enlarged prostate. Partnered with Italy's Recordati, the biotech put out a brief statement blaming the failure on an unexpectedly high placebo response.
Johnson & Johnson's next-gen prostate cancer pill, Zytiga, has been cruising since it hit the market back in April 2011, but now, it may be vulnerable to market share losses for the first time. The FDA has approved Medivation and Astellas' rival, Xtandi, for use in prostate cancer patients before chemo, giving the pill a head-to-head shot at J&J's blockbuster.
Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.
German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.
U.K.'s National Institute for Health and Care Excellence has delivered a blow to Johnson & Johnson's Zytiga in final draft guidance recommending against the prostate cancer pill as a treatment for prostate cancer before chemotherapy. And nobody seems very happy about it--including NICE itself.
Cambridge, MA's Tokai Pharmaceuticals is joining the IPO queue with eyes on $75 million, cash that would get its triple-threat prostate cancer treatment into Phase III trials.
Takeda is walking away from orteronel, its most advanced oncology candidate, after the prostate cancer treatment failed to significantly improve overall survival in two studies, a setback for the company's in-transition Millennium unit.